pegozafermin

News

Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its phase 3 candidate pegozafermin for MASH.

News

BioNTech's vaccine for head and neck cancer has failed a clinical trial, but it will wait for more data before deciding the programme's fate.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.